INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 277 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $474 | +115.5% | 6,922 | +117.3% | 0.00% | +100.0% |
Q1 2024 | $220 | -77.1% | 3,186 | -76.2% | 0.00% | -75.0% |
Q4 2023 | $959 | +28.6% | 13,394 | -6.5% | 0.01% | +33.3% |
Q3 2023 | $746 | -16.9% | 14,327 | +1.1% | 0.01% | -14.3% |
Q2 2023 | $898 | +27.7% | 14,175 | +9.1% | 0.01% | +16.7% |
Q1 2023 | $703 | -11.7% | 12,988 | -13.6% | 0.01% | -14.3% |
Q4 2022 | $796 | -99.9% | 15,036 | +1.4% | 0.01% | 0.0% |
Q3 2022 | $690,000 | -17.6% | 14,823 | +1.1% | 0.01% | -12.5% |
Q2 2022 | $837,000 | +3.8% | 14,662 | +11.3% | 0.01% | +33.3% |
Q1 2022 | $806,000 | -38.1% | 13,172 | -47.0% | 0.01% | +20.0% |
Q4 2021 | $1,302,000 | +177.6% | 24,876 | +97.9% | 0.01% | +25.0% |
Q3 2021 | $469,000 | -13.9% | 12,573 | -5.8% | 0.00% | 0.0% |
Q2 2021 | $545,000 | +132.9% | 13,346 | +93.3% | 0.00% | -55.6% |
Q1 2021 | $234,000 | -1.7% | 6,905 | -7.9% | 0.01% | 0.0% |
Q4 2020 | $238,000 | -13.5% | 7,496 | -6.4% | 0.01% | +80.0% |
Q4 2019 | $275,000 | – | 8,009 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |